Samenvatting
Een icterische epidemie werd voor het eerst beschreven 400 jaar v. Chr. door Hippocrates. Het duurde echter tot 1965 voordat de eerste serologische marker van virale hepatitis werd ontdekt. Blumberg beschreef het ‘Australië’-antigeen dat hij aantoonde in het serum van leukemiepatiënten,[1] dat later de envelop van het hepatitis B-virus (HBsAg) bleek te zijn.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatuur
Blumberg BS, Alter HJ, Visnich S. A ‘new’ antigen in leukemia sera. JAMA 1965;191:541–546.
Feinstone SM, Kapikian AZ, Purceli RH. Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness. Science 1973; 182(116):1026–1028.
Eerden LJ Van Der, Bosman A, Duynhoven YT van. [Surveillance of hepatitis A in the Netherlands 1993–2002]. Nederlands Tijdschrift voor Geneeskunde 2004; 148(28):1390–1394.
Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G,et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998;338(5):286–290.
Fleischer B, Fleischer S, Maier K, Wiedmann KH, Sacher M, Thaler H,et al. Clonal analysis of infiltrating T lymphocytes in liver tissue in viral hepatitis A. Immunology 1990;69(1):14–19.
Lednar WM, Lemon SM, Kirkpatrick JW, Redfield RR, Fields ML, Kelley PW. Frequency of illness associated with epidemic hepatitis A virus infections in adults. American Journal of Epidemiology 1985;122(2):226–233.
Tong MJ, el-Farra NS, Grew MI. Clinical manifestations of hepatitis A: recent experience in a community teaching hospital. J Infect Dis 1995;171(Suppl 1):S15–S18.
Schiff ER. Atypical clinical manifestations of hepatitis A. Vaccine 1992;10(Suppl 1):S18–S20.
Koff RS. Clinical manifestations and diagnosis of hepatitis A virus infection. Vaccine 1992;10(Suppl 1): S15–S17.
Loutan L, Bovier P, Althaus B, Gluck R. Inactivated virosome hepatitis A vaccine. Lancet 1994;343(8893): 322–324.
Van Damme P, Banatvala J, Fay O, Iwarson S, McMahon B, Van Herck K,et al. Hepatitis A booster vaccination: is there a need? Lancet 2003;362(9389):1065–1071.
Winokur PL, Stapleton JT. Immunoglobulin prophylaxis for hepatitis A. Clin Infect Dis 1992;14(2):580–586.
Kane MA, Bradley DW, Shrestha SM, Maynard JE, Cook EH, Mishra RP,et al. Epidemic non-A, non-B hepatitis in Nepal. Recovery of a possible etiologic agent and transmission studies in marmosets. JAMA 1984;252(22):3140–3145.
Koonin EV, Gorbalenya AE, Purdy MA, Rozanov MN, Reyes GR, Bradley DW. Computer-assisted assignment of functional domains in the nonstructural polyprotein of hepatitis E virus: delineation of an additional group of positive-strand RNA plant and animal viruses. Proc Natl Acad Sci USA 1992;89(17):8259–8263.
Lu L, Li C, Hagedorn CH. Phylogenetic analysis of global hepatitis E virus sequences: genetic diversity, subtypes and zoonosis. Reviews in Medical Virology 2006;16(1):5–36.
Khuroo MS. Study of an epidemic of non-A, non-B hepatitis. Possibility of another human hepatitis virus distinct from post-transfusion non-A, non-B type. Am J Med 1980;68(6):818–824.
Emerson SU, Purcell RH. Running like water – the omnipresence of hepatitis E. N Engl J Med 2004; 351(23):2367–2368.
Arankalle VA, Tsarev SA, Chadha MS, Alling DW, Emerson SU, Banerjee K,et al. Age-specific prevalence of antibodies to hepatitis A and E viruses in Pune, India, 1982 and 1992. J Infect Dis 1995;171(2):447–450.
Belabbes EH, Bouguermouh A, Benatallah A, Illoul G. Epidemic non-A, non-B viral hepatitis in Algeria: strong evidence for its spreading by water. Journal of Medical Virology 1985;16(3):257–263.
Tsega E, Krawczynski K, Hansson BG, Nordenfelt E, Negusse Y, Alemu W,et al. Outbreak of acute hepatitis E virus infection among military personnel in northern Ethiopia. Journal of Medical Virology 1991;34(4): 232–236.
Chau TN, Lai ST, Tse C, Ng TK, Leung VK, Lim W,et al. Epidemiology and clinical features of sporadic hepatitis E as compared with hepatitis A. American Journal of Gastroenterology 2006;101(2):292–296.
Khuroo MS, Teli MR, Skidmore S, Sofi MA, Khuroo MI. Incidence and severity of viral hepatitis in pregnancy. Am J Med 1981;70(2):252–255.
Khuroo MS, Kamili S, Dar MY, Moecklii R, Jameel S. Hepatitis E and long-term antibody status. Lancet 1993;341(8856):1355.
Shrestha MP, Scott RM, Joshi DM, Mammen MP Jr, Thapa GB, Thapa N,et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med 2007; 356(9):895–903.
Scaglioni PP, Melegari M, Wands JR. Recent advances in themolecular biology of hepatitis B virus. Bailliere’s Clinical Gastroenterology 1996;10(2):207–225.
Norder H, Courouce AM, Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 1994; 198(2):489–503.
Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus –large-scale analysis using a new genotyping method. J Infect Dis 1997;175(6):1285–1293.
De Franchis RHA, Lau G, Lavanchy D, Lok A, McIntyre N, Mele A,et al. EASL International Consensus Conference on Hepatitis B. 13–14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003;39(Suppl 1):S3–S25.
Kane M. Global programme for control of hepatitis B infection. Vaccine 1995;13(Suppl 1):S47–S49.
Veldhuijzen I, Conyn-van Spaendonck M, Dorigo- Zetsma J. Seroprevalentie van hepatitis B en C in de Nederlandse bevolking. Infectieziekten Bulletin 1999; 10(9):182–184.
Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975;292(15):771–774.
Alter MJ, Hadler SC, Margolis HS, Alexander WJ, Hu PY, Judson FN,et al. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. JAMA 1990;263(9):1218–1222.
McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP,et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985;151(4):599–603.
Tassopoulos NC, Papaevangelou GJ, Sjogren MH, Roumeliotou-Karayannis A, Gerin JL, Purcell RH. Natural history of acute hepatitis B surface antigenpositive hepatitis in Greek adults. Gastroenterology 1987;92(6):1844–1850.
Fattovich G. Natural history of hepatitis B. J Hepatol 2003;39(Suppl 1):S50–S58.
Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM,et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002;35(6):1522–1527.
Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM,et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002;36(2):263–270.
Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A,et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989;2(8663):588–591.
Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A,et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991;32(3):294–298.
Realdi G, Fattovich G, Hadziyannis S, Schalm SW, Almasio P, Sanchez-Tapias J,et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (Eurohep). J Hepatol 1994;21(4):656–666.
Jongh FE de, Janssen HL, Man RA de, Hop WC, Schalm SW, Blankenstein M van. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992;103(5): 1630–1635.
Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(5 Suppl 1):S35–S50.
Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45(2):507–539.
Janssen HL, Zonneveld M van, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y,et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365(9454):123–129.
Lau GK, Tsiang M, Hou J, Yuen S, Carman WF, Zhang L,et al. Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study. Hepatology 2000; 32(2):394–399.
Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R,et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351(12):1206–1217.
Flink HJ, Zonneveld M van, Hansen BE, Man RA de, Schalm SW, Janssen HL. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. American Journal of Gastroenterology 2006;101(2):297–303.
Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z,et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341(17):1256–1263.
Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI,et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339(2):61–68.
Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y,et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357(25):2576–2588.
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M,et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348(9):800–807.
Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML,et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348(9):808–816.
Chang TT, Gish RG, Man R de, Gadano A, Sollano J, Chao YC,et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354(10):1001–1010.
Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z,et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354(10):1011–1020.
Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA,et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359(23):2442–2455.
Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM,et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007;46(1):254–265.
Poland GA. Hepatitis B immunization in health care workers. Dealing with vaccine nonresponse. American Journal of Preventive Medicine 1998;15(1):73–77.
Rizzetto M, Canese MG, Arico S, Crivelli O, Trepo C, Bonino F,et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut 1977;18(12):997–1003.
Rizzetto M, Canese MG, Gerin JL, London WT, Sly DL, Purcell RH. Transmission of the hepatitis B virusassociated delta antigen to chimpanzees. J Infect Dis 1980;141(5):590–602.
Wang KS, Choo QL, Weiner AJ, Ou JH, Najarian RC, Thayer RM,et al. Structure, sequence and expression of the hepatitis delta viral genome. Nature 1986; 323(6088):508–514.
Niro GA, Smedile A, Andriulli A, Rizzetto M, Gerin JL, Casey JL. The predominance of hepatitis delta virus genotype I among chronically infected Italian patients. Hepatology 1997;25(3):728–734.
Gaeta GB, Stroffolini T, Chiaramonte M, Ascione T, Stornaiuolo G, Lobello S,et al. Chronic hepatitis D: a vanishing disease? An Italian multicenter study. Hepatology 2000;32(4 Pt 1):824–827.
Rizzetto M, Ponzetto A, Forzani I. Epidemiology of hepatitis delta virus: overview. Progress in Clinical and Biological Research 1991;364:1–20.
Farci P. Delta hepatitis: an update. J Hepatol 2003; 39(Suppl 1):S212–S219.
Saracco G, Rosina F, Brunetto MR, Amoroso P, Caredda F, Farci P,et al. Rapidly progressive HBsAg-positive hepatitis in Italy. The role of hepatitis delta virus infection. J Hepatol 1987;5(3):274–281.
Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G,et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut 2000;46(3): 420–426.
Aragona M, Macagno S, Caredda F, Crivelli O, Lavarini C, Maran E,et al. Serological response to the hepatitis delta virus in hepatitis D. Lancet 1987;1(8531):478–480.
Buti M, Esteban R, Jardi R, Esteban JI, Guardia J. Serological diagnosis of acute delta hepatitis. Journal of Medical Virology 1986;18(1):81–85.
Wu JC, Chen TZ, Huang YS, Yen FS, Ting LT, Sheng WY,et al. Natural history of hepatitis D viral superinfection: significance of viremia detected by polymerase chain reaction. Gastroenterology 1995;108(3):796–802.
Farci P, Mandas A, Coiana A, Lai ME, Desmet V, Van Eyken P,et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 1994;330(2):88–94.
Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244(4902):359–362.
Major ME, Feinstone SM. The molecular virology of hepatitis C. Hepatology 1997;25(6):1527–1538.
Simmonds P. Variability of hepatitis C virus. Hepatology 1995;21(2):570–583.
Hepatitis C – global prevalence (update). Rélève Épidemiologique Hebdomadaire/Section d’Hygiene du Secretariat de la Societé des Nations = Weekly Epidemiological Record/Health Section of the Secretariat of the League of Nations 1999;74(49):425–427.
Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345(1):41–52.
Hattum J van. Health strategy on HCV in The Netherlands. Acta Gastro-enterologica Belgica 2002;65(2):115–117.
Alter MJ, Gerety RJ, Smallwood LA, Sampliner RE, Tabor E, Deinhardt F,et al. Sporadic non-A, non-B hepatitis: frequency and epidemiology in an urban U.S. population. J Infect Dis 1982;145(6):886–893.
Ohto H, Terazawa S, Sasaki N, Sasaki N, Hino K, Ishiwata C,et al. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med 1994;330(11):744–750.
Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;36(5 Suppl 1):S35–S46.
Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P,et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective followup study of 384 patients. Gastroenterology 1997;112(2): 463–472.
Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D,et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998;28(6):1687–1695.
Planas R, Balleste B, Alvarez MA, Rivera M, Montoliu S, Galeras JA,et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004;40(5):823–830.
Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45(4):529–538.
Farci P, Alter HJ, Wong D, Miller RH, Shih JW, Jett B,et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991;325(2): 98–104.
Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr,et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347(13):975–982.
Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P,et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Annals of Internal Medicine 2004;140(5):346–355.
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R,et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358(9286):958–965.
Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J,et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40(6):993–999.
Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M,et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352(25):2609–2617.
Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J,et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44(1):97–103.
McHutchison JG, Bartenschlager R, Patel K, Pawlotsky JM. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. J Hepatol 2006;44(2):411–421.
Linnen J, Wages J Jr, Zhang-Keck ZY, Fry KE, Krawczynski KZ, Alter H,et al. Molecular cloning and disease association of hepatitis G virus: a transfusiontransmissible agent. Science 1996;271(5248):505–508.
Nishizawa T, Okamoto H, Konishi K, Yoshizawa H, Miyakawa Y, Mayumi M. A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. Biochemical and Biophysical Research Communications 1997; 241(1):92–97.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Bohn Stafleu van Loghum, onderdeel van Springer Uitgeverij
About this chapter
Cite this chapter
Reijnders, J., Janssen, H. (2009). 9 Virale hepatitis. In: Janssen, H., Drenth, J., van Hoek, B. (eds) Leverziekten. Bohn Stafleu van Loghum, Houten. https://doi.org/10.1007/978-90-313-7437-3_9
Download citation
DOI: https://doi.org/10.1007/978-90-313-7437-3_9
Publisher Name: Bohn Stafleu van Loghum, Houten
Print ISBN: 978-90-313-7436-6
Online ISBN: 978-90-313-7437-3
eBook Packages: Dutch language eBook collection